To study the efficacy of intralesional MMR (Measles, Mumps, Rubella) vaccine for treating common warts
Not Applicable
Completed
- Conditions
- Health Condition 1: null- Patients with common warts (Verruca vulgaris)
- Registration Number
- CTRI/2017/09/009870
- Lead Sponsor
- il
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 165
Inclusion Criteria
All consecutive patients and controls of both genders clinically diagnosed with common warts who have not received treatment for their warts in preceding one month
Exclusion Criteria
Pregnant and lactating women, children <12 years, patients with apparent infection or immunosuppression, asthma, allergic skin disorders, meningitis or convulsions
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Resolution of all warts including distant untreated warts, and adverse effectsTimepoint: follow up every 2 weeks at the time of intervention up to 5 injections and then every month for 6 months
- Secondary Outcome Measures
Name Time Method Relapse and Adverse effectsTimepoint: follow up every 2 weeks at the time of intervention up to 5 injections and then every month for 6 months